SCHEMBL6475832

SCHEMBL6475832

CC(C)(C)[Si](C)(C)OCc1ccc(COC(=O)c2ccccc2)c(COC(=O)c2ccccc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
PPARG P37231 1/20 0.42
MAPK1 P28482 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NPC1 O15118 6/20 0.40
RAB9A P51151 6/20 0.40
LMNA P02545 3/20 0.40
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
ADRB3 P13945 1/20 0.40
SMN1; SMN2 Q16637 5/20 0.39
ALDH1A1 P00352 4/20 0.39
MAPT P10636 2/20 0.39
HIF1A Q16665 1/20 0.39
POLB P06746 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2873628 0.90 KMT2A (0.43) KMT2ATDP1SLC6A2SLC6A3PPARG
SCHEMBL6472102 0.77 TDP1 (0.57) KMT2ATDP1SLC6A2SLC6A3PPARG
SCHEMBL16610042 0.77 KMT2A (0.58) KMT2ATDP1LMNAADRB2ADRB1
SCHEMBL16610043 0.77 MAPT (0.55) KMT2ATDP1SLC6A2SLC6A3PPARG
SCHEMBL3280491 0.76 TDP1 (0.56) KMT2ATDP1SLC6A2SLC6A3PPARG
SCHEMBL28498515 0.76 MAPK1 (0.50) KMT2ATDP1SLC6A2SLC6A3MAPK1
SCHEMBL6156231 0.76 MAOB (0.41) KMT2A
SCHEMBL8879060 0.75 TDP1 (0.44) KMT2ATDP1SLC6A2SLC6A3PPARG
SCHEMBL25187553 0.75 TDP1 (0.51) KMT2ATDP1SLC6A2SLC6A3NPC1
SCHEMBL5341608 0.75 MRGPRX4 (0.52) NPSR1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924400-B2 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2005-08-02 US disclosed
US-6831106-B1 Selective activity on cell proliferation and differentiation without displaying any hypercalcaemiant nature GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-12-14 US disclosed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US disclosed
US-20030195259-A1 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195259-A1 Triaromatic vitamin D analogues CYP24A1, CYP2R1, VDR KMT2A 4353/4885TDP1 1791/4885SLC6A2 4665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.